Pharma Cos Sign €40M Deal To Market Hearing Loss Drug
Specialty pharma business Norgine BV has secured an exclusive licensing agreement worth €40 million ($43 million) to sell a medication that reduces the risk of hearing loss in young chemotherapy patients, the...To view the full article, register now.
Already a subscriber? Click here to view full article